Anti-thymocyte globulin (rabbit) - Biologic Drug Details

Summary for anti-thymocyte globulin (rabbit)

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for anti-thymocyte globulin (rabbit)

Recent Clinical Trials for anti-thymocyte globulin (rabbit)

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
University of Alabama at Birmingham	PHASE2
Peking University People's Hospital	PHASE2
Northwell Health	PHASE1

See all anti-thymocyte globulin (rabbit) clinical trials

Pharmacology for anti-thymocyte globulin (rabbit)

Mechanism of Action	Antibody-Surface Protein Interactions
Physiological Effect	Increased T Lymphocyte Destruction Lymphocyte Function Alteration
Established Pharmacologic Class	Immunoglobulin G
Chemical Structure	Immunoglobulins

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for anti-thymocyte globulin (rabbit) Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for anti-thymocyte globulin (rabbit) Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for anti-thymocyte globulin (rabbit) Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Anti-Thymocyte Globulin (Rabbit)

Last updated: February 15, 2026

What Is the Current Market for Anti-Thymocyte Globulin (Rabbit)?

Anti-thymocyte globulin (rabbit) (ATG-R) is a polyclonal antibody used primarily for immune suppression in transplantation, aplastic anemia, and certain autoimmune diseases. It acts by depleting T-cells, reducing immune response.

In 2022, the global ATG-R market was valued at approximately USD 350 million. By 2030, forecasts project a compound annual growth rate (CAGR) of 7.5%, reaching nearly USD 620 million. Growth factors include rising organ transplant procedures, expanding applications in autoimmune conditions, and increased adoption of ATG-R over horse-derived formulations.

Key market players include Genzyme (Sanofi), Merck KGaA, and Fresenius. Genzyme's Thymoglobulin remains the dominant product with about 65% market share in 2022.

What Are the Drivers of Market Growth?

Expansion in Transplantation Procedures

T cell depletion remains essential in hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT). The increasing number of transplants globally drives ATG-R demand.

• The International Registry of Organ Donation and Transplantation reported over 2 million transplants worldwide in 2021, up 8% from 2019.
• Countries like the US, China, and India account for significant growth due to expanding healthcare infrastructure.

Innovations in Autoimmune Disease Treatment

ATG-R has received approval for aplastic anemia and graft-versus-host disease (GVHD).

• The treatment landscape for autoimmune conditions like multiple sclerosis and autoimmune hemolytic anemia is evolving, with ATG-R increasingly integrated into protocols.
• Clinical trials exploring ATG-R in other autoimmune disorders influence future demand.

Preference for Rabbit-Derived Formulations

Rabbit ATG formulations are preferred over horse-derived ones due to better efficacy and lower infusion-related reactions.

• Clinical studies demonstrate higher T-cell depletion with rabbit sources, influencing physician choices.

What Are the Challenges and Constraints?

Supply Chain Limitations

Manufacturing ATG-R involves complex biological processes, leading to high production costs and potential supply disruptions.

• The limited number of manufacturing facilities (roughly 4 globally) constrains supply.
• Regulatory approvals for manufacturing sites impact capacity expansion.

Competition and Pricing Pressures

Market entry of biosimilars and generic agents could pressure pricing.

• No biosimilars for ATG-R currently approved; however, patent expiries for related biologics could inspire future entrants.
• Pricing varies regionally; in North America, a standard dose (12 mg/kg) costs around USD 15,000.

Regulatory and Reimbursement Policies

Pricing and reimbursement policies influence market access.

• In the US, Medicare and Medicaid reimbursements impact prescribing patterns.
• Several countries enforce price controls, restricting profit margins.

What Is the Financial Trajectory?

Revenue Projections

Analysts forecast steady revenue growth driven by increased transplant activity and expanded indications.

Year	Market Revenue (USD millions)	Growth Rate	Notes
2022	350	-	Baseline
2025	470	8.2% CAGR	Adoption in autoimmune diseases accelerates
2030	620	7.5% CAGR	Market maturation; potential new indications

Profitability Outlook

Gross margins for ATG-R are approximately 50-60%, given manufacturing complexities. Price erosion could impact margins, but high demand stabilizes revenue streams.

Investment Considerations

• Companies investing in manufacturing capacity modernization could capitalize on increased demand.
• R&D for novel formulations or improved administration routes may extend product lifecycle.

How Do Regional Markets Differ?

North America

Dominant market with high transplant rates, reimbursement systems favoring biologic use, and established manufacturing infrastructure.

Europe

Similar to North America but facing more price regulation. Market growth is driven by expanding indications and EU approvals.

Asia-Pacific

Fastest growth with rising transplant procedures. Challenges include regulatory navigation and supply chain development.

What Future Trends Will Shape the Market?

Regulatory Approvals

• Expansion of ATG-R approvals for new indications such as autoimmune diseases.
• Increased focus on biosimilars pending patent expiration.

Manufacturing Innovations

• Adoption of continuous manufacturing processes to reduce costs.
• Investment in capacity expansion in Asia-Pacific regions.

Competitive Landscape

• Potential entry of biosimilar products from emerging biotech firms.
• Strategic partnerships between manufacturers and healthcare providers.

Key Takeaways

• The ATG-R market is expected to grow at a CAGR of approximately 7.5%, reaching USD 620 million by 2030.
• Demand is driven by rising transplant procedures, expanding autoimmune indications, and preference for rabbit formulations.
• Supply chain limitations and regulatory hurdles challenge market expansion.
• Pricing pressures could affect profitability, especially with biosimilar competition on the horizon.
• Opportunities exist in expanding indications, manufacturing efficiencies, and regional market penetration.

FAQs

1. How does rabbit ATG compare to horse-derived formulations?
Rabbit ATG offers higher efficacy in T-cell depletion and better tolerability, making it the preferred choice in most clinical settings.

2. Are biosimilars expected for ATG-R?
Currently, no biosimilars have been approved, but patent expiries could prompt biosimilar development in the future.

3. What regions will drive the most growth?
Asia-Pacific exhibits the fastest growth, driven by increasing transplant activity. North America and Europe will maintain stable markets with high adoption rates.

4. What are the main clinical applications of ATG-R?
Primarily used in hematopoietic stem cell transplantation, solid organ transplantation, and treatment of autoimmune diseases like aplastic anemia.

5. What are the primary challenges facing manufacturers?
Supply chain limitations, high manufacturing costs, regulatory approvals, and potential price-based competition.

---

Sources:

[1] Market research estimates and forecasts from GlobalData and Grand View Research.
[2] Clinical data and usage trends from PubMed and FDA approvals.
[3] Pricing and reimbursement information from Centers for Medicare & Medicaid Services and regional health authorities.